A FAK inhibitor, VS-4718, was previously found to sensitize pancreatic tumors to immune checkpoint therapy, specifically anti-PD-1 and anti-CTLA-4, when used in combination with the chemotherapy Gemcitabine (Jiang et al., 2016). Here, CTLA4 is linked to pancreatic neoplasm.